AlphAIAlphAI — Financial news for AI agents
investing.comOCT 272 min read$GMAB

JPMorgan upgrades Genmab stock rating on drug trial outlook

JPMorgan upgraded Genmab (GMAB) to Overweight, raising its price target to DKK3,500. The move follows a 68% stock surge and ahead of a key Phase III trial readout. JPMorgan expects a positive outcome and raised peak sales forecasts for peto to $5B. Genmab reported 25% revenue growth in H1 and exceeded earnings estimates.

Original reporting
investing.com
Published Oct 27, 2026, 8:21 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 27, 2026, 8:28 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefFinancial news
Primary signal
$GMAB
Bullish
high confidence
Mentioned
$GMAB
Relevance
7/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$GMABBullishHigh
01

Why it matters

The upgrade may trigger buying pressure ahead of the trial, but the magnitude depends on the actual data release.

02

Market read

Analyst upgrade with a higher price target provides a fresh catalyst for Genmab, potentially influencing biotech sector sentiment.

03

What to watch

Potential competition from other head‑and‑neck therapies and currency risk on DKK‑denominated targets.

Relevance 7/10Novelty 7/10Timing: pre‑market today

Background

JPMorgan’s coverage upgrade follows recent positive data from Genmab’s Rina‑S and Epkinly trials and precedes the upcoming peto Phase III readout.

Company-level read

Ticker impact

$GMABBullishHigh confidence
Context

JPMorgan upgraded Genmab to Overweight, raised price target to DKK3,500 and expects a positive Phase III readout for its peto trial.

Expected impact

likely upward pressure as investors price in the upgraded rating and trial optimism

Evidence & confidence

The upgrade is a fresh, primary disclosure with a concrete price target and a clear catalyst (upcoming Phase III data).

Market effects

Sector

Boosts sentiment for biotech firms with late‑stage oncology pipelines.

Regional

May lift European biotech indices where Genmab is a component.

Global

Limited to investors tracking oncology trial outcomes and JPMorgan’s coverage universe.

Counterpoint

What could challenge this read

If the Phase III readout disappoints, the upgrade could reverse sharply.

Key entities

  • company
    Genmab A/S

    Danish biotech developing oncology antibodies.

  • analyst_firm
    JPMorgan

    Issued the Overweight upgrade and new price target.

Read at source← All news

StoryJPMorgan upgrades Genmab to Overweight and raises price target to DKK3,500

Related articles

OCT 27
$GMABHighAI 8/10

J.P. Morgan upgrades Genmab on cancer drug growth potential

J.P. Morgan upgraded Genmab to 'overweight' and raised its price target to DKr3,500, citing expected positive results from a late-stage trial of its cancer drug petosemtamab. The brokerage anticipates a response rate of at least 40% in head and neck cancer patients, raising its peak sales forecast to $5 billion. It also increased sales forecasts for other drugs, Rina-S and Epkinly, and adjusted its revenue and earnings per share estimates.

finance.yahoo.com2 min
OCT 26
$GMABMedAI 8/10

Genmab A/S Announces Updated Phase 2 Data Demonstrating More Than Two-Year Median Overall Survival With Petosemtamab Plus Pembrolizumab In First-Line Recurrent/Metastatic Head And Neck Squamous Cell Carcinoma

Genmab A/S reported updated Phase 2 trial data for petosemtamab plus pembrolizumab in recurrent/metastatic head and neck squamous cell carcinoma. The combination achieved a median overall survival of 28.2 months, an overall response rate of 63%, and a median progression-free survival of 9.0 months. The findings were presented at the ESMO Congress 2026. The company is also conducting four Phase 3 trials for petosemtamab in various cancer types.

marketscreener.com5 min
OCT 26
$GMABMedAI 8/10

Genmab's Encouraging Oncology Data Boosts Investor Optimism

Genmab (GMAB) presented positive Phase 2 data for petosemtamab in head and neck cancer, showing 28.2-month median survival and 63% response rate. It also reported promising results in metastatic colorectal cancer. Genmab partnered with Incyte (INCY) for a Phase 1/2 trial. GMAB shares rose 1.56% to $44.93, a 52-week high.

finance.yahoo.com2 min
OCT 26
$GMABHighAI 9/10

Genmab’s ADC beats survival expectations in Phase 3 ovarian cancer trial

Genmab's rinatabart sesutecan (Rina-S) showed a 71% reduction in disease progression or death and a 57% reduction in death risk in a Phase 3 ovarian cancer trial, exceeding expectations. Analysts predict it could challenge AbbVie's Elahere. Genmab's stock rose over 8%. The company plans regulatory discussions and potential 2027 U.S. launch.

biospace.com2 min
OCT 26
$GMABMedAI 9/10

Genmab Phase 2 Trial Reports 28.2-Month Cancer Survival

Genmab reported Phase 2 trial results showing 28.2-month median overall survival for petosemtamab plus pembrolizumab in PD-L1-positive head and neck cancer. The combination achieved a 63% response rate and 9.0-month progression-free survival. Genmab plans Phase 3 results in 2026.

grafa.com2 min